Monographie - Insulin lyspro

Siste oppdatering :
14/12/2024

Insulin lyspro

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Humalog

Argentina, Belgia, Canada, Chile, Colombia, Danmark, Ecuador, Finland, Frankrike, Hellas, Irland, Island, Italia, Japan, Kroatia, Luxembourg, Malaysia, Marokko, Mexico, Nederland, Norge, Polen, Portugal, Romania, Saudi-Arabia, Slovenia, Spania, Storbritannia, Sveits, Sverige, Sør-Afrika, Tyrkia, Tyskland, Ungarn, USA, Venezuela, Østerrike

Referanser : Insulin lyspro

	Type	publikasjon
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3149	Journal	DeFelippis MR, Bell MA, Heyob JA, Storms SM. In Vitro Stability of Insulin Lispro in Continuous Subcutaneous Insulin Infusion. Diabetes Tech and Ther 2006 ; 8, 3: 358-368.
3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
4433	Journal	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4650	Labratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021

Mentions Légales